By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: HUTCHMED to Announce 2025 Final Results
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > HUTCHMED to Announce 2025 Final Results
HUTCHMED to Announce 2025 Final Results
Health

HUTCHMED to Announce 2025 Final Results

GlobeNews Wire
Last updated: 06/02/2026 2:36 PM
GlobeNews Wire
Published: 06/02/2026
Share
SHARE

February 06, 2026 03:30 ET  | Source: HUTCHMED (China) Limited

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).

Both webcasts will be available live via the website of the Company at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries +852 2121 8200 / ir@hutch-med.com
   
Media Enquiries  
FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com
     Ben Atwell / Tim Stamper      +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
   
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
   
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
   
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000
Alcatraz Appoints Security Industry Veteran Erik Nord to Lead Business Development in Europe
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
DAR GLOBAL RINGS THE LONDON STOCK EXCHANGE OPENING BELL, ANCHORING GLOBAL EXPANSION WITH LAUNCH OF ‘LIVE ALL IN’ SLOGAN
Reebok and SOUTH2 WEST8 Reunite for Third Collaboration, Introducing the IPF Mule
Curium Announces First Commercial Doses of PYLCLARI for Patients with Prostate Cancer in Poland
TAGGED:2025announcefinalHKSE:0013hutchmedKYG4672N1198LSE:HCMNasdaq:HCMnewsresultsUS44842L1035
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Health

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNews Wire
GlobeNews Wire
13/08/2025
Saudi Minister of Industry and Mineral Resources, Bandar bin Ibrahim Alkhorayef, Elected President of the 21st UNIDO General Conference
Crossover Markets Announces Record Results
HTX 2025 Mid-Year Security Report: Upgrading a Multi-Layered Defense for a Safer Crypto Ecosystem
IvoryLab fast-tracks development with support from the Telnyx AI Accelerator
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?